Detalles de la búsqueda
1.
Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.
Reprod Biol Endocrinol
; 21(1): 45, 2023 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37194068
2.
A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Hum Reprod
; 37(6): 1161-1174, 2022 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35451013
3.
Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Reprod Biol Endocrinol
; 20(1): 147, 2022 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195924
4.
A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Hum Reprod
; 36(9): 2452-2462, 2021 08 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34179971
5.
Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
Reprod Biomed Online
; 43(6): 1019-1026, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34756645
6.
First pre-filled pen device with highly purified human menopausal gonadotropin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution.
Int J Clin Pharmacol Ther
; 59(12): 794-803, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34622768
7.
Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta.
J Assist Reprod Genet
; 38(10): 2651-2661, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34254211
8.
Anti-Müllerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta.
Clin Endocrinol (Oxf)
; 90(5): 719-726, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30801744
9.
Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.
Reprod Biomed Online
; 38(4): 528-537, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30713022
10.
Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial.
Reprod Biomed Online
; 38(2): 195-205, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30594482
11.
Response to: Comparison between follitropin delta and follitropin alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms!
Reprod Biomed Online
; 45(3): 625, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35597756
12.
Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049).
Clin Endocrinol (Oxf)
; 83(6): 902-12, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26202150
13.
Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol.
Hum Reprod
; 29(8): 1688-97, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24903202
14.
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial.
Reprod Biomed Online
; 28(4): 462-8, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24581989
15.
Corrigendum: Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosing.
Front Endocrinol (Lausanne)
; 15: 1397017, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38577569
16.
High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
Hum Reprod
; 28(2): 442-52, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23136144
17.
Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation.
Reprod Biol Endocrinol
; 11: 90, 2013 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24028076
18.
Ganirelix and the prevention of premature luteinizing hormone surges.
F S Rep
; 4(2 Suppl): 56-61, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37223764
19.
Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome.
Hum Reprod
; 27(7): 2177-85, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22587997
20.
Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
Reprod Biomed Online
; 24(4): 410-9, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22386594